Better Health for All

Soligenix is a late-stage biopharmaceutical company entirely focused on developing and commercializing products to treat rare diseases with unmet medical needs, such as cutaneous T-cell lymphoma (CTCL), oral mucositis, and Behçet's Disease.

Its pipeline also includes vaccines for ricin toxin, filoviruses (Marburg, Ebola), and COVID-19, indicating a strong commitment to disease prevention. All products are designed to provide substantial health benefits, with no evidence of negative health impacts. The company's focus on orphan diseases and conditions prevalent in regions like the Middle East and East Asia demonstrates efforts to reach vulnerable populations. Soligenix has received an FDA Orphan Products Development grant of $2.6 million over 4 years to support expanded treatment for CTCL, including home use. During public health emergencies, the company contributes by developing vaccines for COVID-19 and filoviruses. Soligenix conducts Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trials with a Data Monitoring Committee for interim analysis, indicating robust ethical standards in research. The company's press releases include forward-looking statements and disclaimers regarding the uncertainty of clinical trial outcomes and regulatory approvals, as well as risks related to funding, competition, and healthcare reform. The company holds proprietary patents for its technologies like ThermoVax® and synthetic hypericin, with some patents expiring in 2036.

Fair Money & Economic Opportunity

Soligenix, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat rare diseases.

Its business model centers on research, clinical trials, and regulatory approvals for pharmaceutical products. The company does not offer lending, deposit, or other financial services to consumers. Therefore, all KPIs related to fair money and economic opportunity, such as underserved client share, pricing fairness, exploitative fees, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy, debt burden, geographic inclusion for banking, and product simplicity for financial products, are not applicable to its operations.

Fair Pay & Worker Respect

No specific data or mention of Soligenix, Inc. (SNGX.US) was found in the provided articles regarding any of the Fair Pay & Worker Respect KPIs.

The articles discuss general best practices for pay equity and employee engagement but do not contain company-specific metrics or information for SNGX.US.

Kind to Animals

Soligenix's animal testing policy is governed by the FDA Animal Rule (21 CFR 601.90), which mandates animal studies for efficacy of products like RiVax where human trials would be unethical.

This rule requires efficacy evaluation in animal models, combining safety studies in humans with efficacy testing in animals to facilitate approval. The company uses non-human primates (NHPs), mice, and rats in preclinical immunogenicity challenge studies for RiVax, demonstrating 100% protection in these animal models. The company does not explicitly mention alternative testing methods to animal testing, relying on in vivo tests for efficacy. Soligenix has received over $40 million in non-dilutive government funding for RiVax development, but less than 1% of its R&D spending supports the development of non-animal methods. The company participates in industry forums and collaborations, such as with the Wadsworth Center and the University of Texas Southwestern, but there is no evidence of formal commitments or significant contributions to animal-free testing standards. Soligenix engages with the FDA through the Animal Rule pathway and has engaged with patient advocacy groups, leading to Orphan Drug and Fast Track designations for HyBryte, and with the FDA and EMA via the Scientific Advice process for SGX942.

No War, No Weapons

Soligenix's core business is biopharmaceuticals for rare diseases and public health, and the company does not engage in arms contracts.

However, it develops products with dual-use potential. For example, it is developing therapies for melioidosis, which is considered a possible biological warfare agent, and OrbeShield for gastrointestinal acute radiation syndrome, which can result from radiation exposure. Additionally, its vaccines for Ebola and Marburg viruses, while intended for public health, could also serve biodefense purposes. These technologies prioritize civilian health needs but have potential military applications. Dr. Christopher J. Schaber, a member of Soligenix's board of directors, has also been on the board of the Alliance for Biosecurity since October 2014. However, there is no specific information regarding the board's direct oversight over defense-related business activities.

Planet-Friendly Business

Soligenix mentions an expanded Corporate Social Responsibility program that includes environmental sustainability, with a commitment to reducing greenhouse gas emissions and carbon footprint, and efforts to reduce plastic and paper waste, and promote recycling.

However, no specific quantitative data, metrics, or outcomes are provided in the available articles to assess performance against any of the detailed Planet-Friendly Business KPIs.

Respect for Cultures & Communities

The provided articles do not contain specific, concrete data points or facts to assess Soligenix, Inc. against any of the KPIs for the 'Respect for Cultures & Communities' value. Information regarding formal partnerships with indigenous or local community groups, revenue reinvested in local development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, community grievance mechanisms, complaint resolution times, FPIC participation, community governance inclusion, cultural preservation investment, local procurement, indigenous suppliers, cultural site protection, social license to operate, charitable giving to cultural organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion is absent.

While the company collaborates with the University of Hawaiʻi at Mānoa's John A. Burns School of Medicine, which focuses on Native Hawaiian health, this does not directly provide evidence for Soligenix's own actions or metrics related to community engagement or cultural respect as defined by the rubric's KPIs.

Safe & Smart Tech

The company allows users to review, update, correct, or delete their personal information by contacting them via email, and provides opt-out options for emails and cookies.

However, the site explicitly states it does not accept or process Do Not Track signals. The company indicates it will release user information to comply with the law, including subpoenas, and will make legally required disclosures of data breaches. The site is intended for users in the United States. There is no evidence of a clear stance or advocacy for digital rights, and the lack of DNT processing suggests a limited commitment to user privacy preferences.

Zero Waste & Sustainable Products

No specific, concrete evidence was found in the provided articles regarding Soligenix, Inc.'s performance on any of the 'Zero Waste & Sustainable Products' KPIs. The articles did not contain data on waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education for Soligenix, Inc.

Information about a third-party service provider's offerings was present but did not indicate Soligenix's utilization or performance.